Helius Medical Technologies, Inc. (HSDT)
NASDAQ: HSDT · IEX Real-Time Price · USD
0.850
-0.018 (-2.07%)
At close: Jul 19, 2024, 4:00 PM
0.860
+0.010 (1.18%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Company Description
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma.
The company’s product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.
Helius Medical Technologies, Inc. was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.
Helius Medical Technologies, Inc.
| Country | United States |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Dane Carl Andreeff |
Contact Details
Address: 642 Newtown Yardley Road Newtown, Pennsylvania 18940 United States | |
| Phone | 215-944-6100 |
| Website | heliusmedical.com |
Stock Details
| Ticker Symbol | HSDT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001610853 |
| CUSIP Number | 42328V504 |
| ISIN Number | US42328V8019 |
| Employer ID | 36-4787690 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Dane Carl Andreeff | President, Chief Executive Officer and Director |
| Jeffrey S. Mathiesen CPA | Chief Financial Officer, Treasurer, Secretary and Director |
| Dr. Antonella Favit-Van Pelt M.D., Ph.D. | Chief Medical Officer |
| Lawrence Picciano | Senior Vice President of Engineering, Quality and Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 28, 2024 | 8-K | Current Report |
| Jun 20, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 3, 2024 | 8-K | Current Report |
| May 31, 2024 | 8-K | Current Report |
| May 31, 2024 | ARS | Filing |
| May 31, 2024 | DEF 14A | Other definitive proxy statements |
| May 30, 2024 | SD | Form - SD |
| May 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| May 13, 2024 | 10-Q | Quarterly Report |
| May 13, 2024 | 8-K | Current Report |